Creative Biolabs offers necrosis- or DNA-targeted IL-12 development to safely deliver high-potency cytokine payloads only to the tumor core. Maximize anti-tumor effect and eliminate systemic toxicity.
Learn More →Targeted IL-12 Delivery Engineering Services
Our primary mission at Creative Biolabs is to transform the high-potency, high-toxicity profile of free interleukin-12 (IL-12) into a high-precision, high-safety therapeutic agent. We solve the fundamental clinical limitation of systemic IL-12 administration by engineering customized delivery systems. These systems ensure that IL-12 is synthesized, anchored, or released only within the tumor microenvironment (TME). This localized approach maximizes therapeutic efficacy while minimizing the dangerous systemic side effects historically associated with IL-12 therapy.
Background Featured Services What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Introduction: Unleashing the Undisputed Power of IL-12
IL-12 is a cornerstone of cancer immunotherapy, acting as a "master regulator" that drives T helper type 1 (TH1) differentiation, activates natural killer (NK) cells, and boosts cytotoxic potential of T lymphocytes (CTLs) for robust anti-tumor immunity. However, its systemic administration is notoriously hampered by a short half-life and severe, dose-limiting toxicity. At Creative Biolabs, we specialize in overcoming this by offering targeted IL-12 delivery engineering services. We use our two decades of expertise to confine this powerful payload directly to the TME, maximizing the therapeutic index while minimizing systemic risk.
Our Featured Services
Necrosis- or DNA targeted IL-12 Development
Fibronectin targeted IL-12 Development
Maximize IL-12 efficacy and safety with Creative Biolabs' fibronectin-targeted IL-12 service. We engineer constructs that anchor the potent cytokine to the tumor ECM, ensuring localized, sustained action.
Learn More →HER2/Mesothelin/CD30 targeted IL-12 Development
Creative Biolabs engineers next-generation IL-12 therapeutics specifically targeting HER2, mesothelin, and CD30. Our service enhances specificity and safety, turning highly potent IL-12 into a precise, tumor-restricted treatment.
Learn More →Key Deliverables and Problem-Solving Capabilities
Adoptive Cell Therapies (ACT) Safety Switches (Smart Factory)
We engineer CAR-T/TCR-T cells with NFAT-responsive promoters for inducible IL-12 secretion, ensuring the payload releases only upon antigen detection to prevent systemic cytokine release syndrome (CRS).
Extracellular Matrix (ECM)-Targeting Immunocytokines
Our design uses collagen-binding domains to fuse IL-12 for ECM targeting, creating a sustained-release depot in the TME to overcome immunosuppression.
Precision Gene Therapy Vectors
We develop targeted vectors (AAV/OIV) to express IL-12 in situ, turning the tumor into an inflammatory immune hub by delivering the gene directly to cancer cells.
Discover how we can help - Request a consultation to map our IL-12 delivery platforms to your specific oncology target.
Workflow: From Concept to Clinically Relevant Construct
Our multi-stage workflow is designed for transparency, rigor, and rapid iteration, ensuring clear milestones and decision points for our clients.
Publication
This review provides a comprehensive overview of the advances in IL-12-based tumor immunotherapy, systematically categorizing and evaluating the different delivery platforms. These strategies include:
- Protein Engineering: Modifying IL-12 through fusion with proteins that target the tumor extracellular matrix or specific immune factors to enhance tumor accumulation and safety.
- Viral Vectors: Utilizing a variety of oncolytic viruses to infect tumor cells and achieve localized, sustained expression of IL-12.
- Non-Viral Vectors: Employing chemical-based systems like polymer and lipid nanoparticles (LNPs), as well as bio-derived vectors like exosomes, for efficient and less immunogenic nucleic acid (DNA/mRNA) delivery.
- Cellular Carriers: Engineering cells—such as dendritic cells, T cells, and mesenchymal stromal cells—to serve as living factories for the targeted production and delivery of IL-12 directly within tumors.
Fig.1 Optimizing IL-12 delivery for antitumor activity. 1
Why Choose Us?
Choosing Creative Biolabs means partnering with a leader to develop a clinically viable, safer, and more effective next-generation IL-12 therapeutic. We implement validated inducible safety systems, such as NFAT-responsive promoters in ACT platforms, ensuring conditional IL-12 secretion upon tumor engagement, drastically lowering toxicity. We also specialize in strategic TME remodeling, converting "cold" tumors into "hot" immune lesions by dramatically reducing MDSCs and Treg cells, leading to a ~75% increase in T-cell infiltration. Rigorous QC/QA and superior PK/PD profiles consistently demonstrate a ~60% reduction in systemic toxicity markers.
Experience the Creative Biolabs advantage - Get a quote today to start leveraging our platform expertise for your project.
FAQs
Q: How do your targeted systems guarantee safety compared to systemic IL-12?
A: Our primary method for enhancing safety is localization. By engineering the IL-12 payload to only be released or anchored within the tumor, we drastically reduce systemic exposure. This minimizes the risk of dangerous side effects like CRS while still providing the required therapeutic dose locally.
Q: My current IL-12 fusion protein showed limited efficacy. How will your optimization services improve this?
A: Our optimization focuses on enhancing tumor retention through ECM-targeting domains or by designing formulations that physically trap the therapeutic at the injection site for a prolonged period. This ensures sustained immune stimulation, which is key to long-term efficacy.
Q: Can your IL-12 delivery systems be used for "cold" tumors that are non-responsive to ICI?
A: Absolutely. The potent, localized IL-12 burst effectively remodels the highly immunosuppressive TME, dramatically reducing MDSCs and Treg cells. This makes the "cold" tumor highly susceptible to combination treatments like ICI, offering a pathway for previously refractory cancers.
Customer Review
-
High TME Concentration
Using Creative Biolabs' services in our research has significantly improved the signal-to-noise ratio of our therapeutic agent. The ECM-targeting fusion drastically reduced systemic IFN-γ side effects, allowing us to safely escalate the local dose, which was critical for penetrating dense tumor stroma. - Dr. A***n -
Cold Tumor Conversion
Creative Biolabs' tAAV9-IL-12 construct delivered unparalleled results in our cold pancreatic cancer model. We saw a dramatic and sustained reduction in both MDSCs and Treg cells in the TME post-treatment, effectively converting the tumor into an immune-responsive lesion. - Prof. J***l M
Related Services
To further enhance your immuno-oncology program, Creative Biolabs offers several complementary services:
TCR Generation and Optimization
Creative Biolabs offers comprehensive, one-stop TCR engineering T cell early development services, covering biomarker identification, TCR generation/optimization, delivery, in vitro validation, and in vivo testing.
Learn More →Dendritic Cell Engineering Service
Creative Biolabs offers DC engineering services, leveraging the antigen-presenting cell function of DCs to enhance their ability to initiate and regulate T cell-mediated immune responses against disease.
Learn More →How to Contact Creative Biolabs
Ready to achieve superior efficacy and safety in your IL-12 project? Our expert team is prepared to guide you through the process, from initial design consultation to final preclinical validation.
Contact Our Team for More Information and to Discuss Your Project
Reference
- Dong, Chunyan, et al. "Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy." Current Issues in Molecular Biology 46.10 (2024): 11548-79. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cimb46100686
Download our brochureLoading case studies...
Online Inquiry